The ERK inhibitor PD98059 attenuates the phosphorylation of VEGF and VEGFR2 expression through HSPA12A and attenuates angiogenic features in vitro; knockdown of HSPA12A in mice impairs cardiac angiogenesis after myocardial infarction and exacerbates cardiac dysfunction (Li et al., 2022). This evidence concerns the gene MAPK1 and myocardial infarction.